JP6781701B2 - 口内炎用のカルシウムおよびリン酸塩の製剤 - Google Patents

口内炎用のカルシウムおよびリン酸塩の製剤 Download PDF

Info

Publication number
JP6781701B2
JP6781701B2 JP2017533337A JP2017533337A JP6781701B2 JP 6781701 B2 JP6781701 B2 JP 6781701B2 JP 2017533337 A JP2017533337 A JP 2017533337A JP 2017533337 A JP2017533337 A JP 2017533337A JP 6781701 B2 JP6781701 B2 JP 6781701B2
Authority
JP
Japan
Prior art keywords
powder
calcium
phosphate
liquid composition
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017533337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505862A5 (enExample
JP2018505862A (ja
Inventor
ウェルドン，バーソロミュー
コバス，エドワード
デュムラン，サンドリーヌ
ベタンコート，エイメスター
ゴセリン，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch Health Americas Inc
Original Assignee
Valeant Pharmaceuticals International Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals International Inc USA filed Critical Valeant Pharmaceuticals International Inc USA
Publication of JP2018505862A publication Critical patent/JP2018505862A/ja
Publication of JP2018505862A5 publication Critical patent/JP2018505862A5/ja
Application granted granted Critical
Publication of JP6781701B2 publication Critical patent/JP6781701B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017533337A 2014-12-17 2015-12-15 口内炎用のカルシウムおよびリン酸塩の製剤 Active JP6781701B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093026P 2014-12-17 2014-12-17
US62/093,026 2014-12-17
PCT/CA2015/051327 WO2016095036A1 (en) 2014-12-17 2015-12-15 Formulations of calcium and phosphate for oral inflammation

Publications (3)

Publication Number Publication Date
JP2018505862A JP2018505862A (ja) 2018-03-01
JP2018505862A5 JP2018505862A5 (enExample) 2019-01-31
JP6781701B2 true JP6781701B2 (ja) 2020-11-04

Family

ID=56125518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017533337A Active JP6781701B2 (ja) 2014-12-17 2015-12-15 口内炎用のカルシウムおよびリン酸塩の製剤

Country Status (10)

Country Link
US (2) US11590165B2 (enExample)
EP (1) EP3233092B1 (enExample)
JP (1) JP6781701B2 (enExample)
KR (1) KR102397070B1 (enExample)
CN (1) CN107530374B (enExample)
AU (1) AU2015367208B2 (enExample)
BR (1) BR112017013158B1 (enExample)
CA (1) CA2971224C (enExample)
MX (1) MX372952B (enExample)
WO (1) WO2016095036A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765650B2 (en) * 2016-02-03 2020-09-08 Forward Science Technologies, LLC Artificial saliva
US10143635B2 (en) * 2016-02-03 2018-12-04 Forward Science Technologies, LLC Artificial saliva
GR1009399B (el) * 2017-06-23 2018-11-15 Χρηστος Γεωργιου Φυτας Στοματικο διαλυμα κατα της ξηροστομιας και στοματοφαρυγγικης βλεννογονιτιδας
WO2023183556A2 (en) * 2022-03-24 2023-09-28 Amcyte Pharma, Inc. Treatment for retinal disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB572352A (en) * 1944-02-26 1945-10-03 Charles Somerville Dillon Improved tooth powder or preparation
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5540913A (en) 1987-03-17 1996-07-30 Turner; Robert E. Formulations and uses thereof in the prevention and treatment of oral lesions
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
US5427768A (en) 1993-06-23 1995-06-27 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
AU695356B2 (en) * 1995-02-24 1998-08-13 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
MX9801063A (es) 1995-08-08 1998-05-31 Enamelon Inc Productos y metodos mejorados para la remineralizacion de lesiones en dientes.
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
PT939613E (pt) * 1996-09-18 2003-07-31 Erling Johansen Solucao sobressaturada para lavagem bucal contendo ioes calcio e fosfato
US6159448A (en) * 1996-09-27 2000-12-12 Enamelon, Inc. Products and methods for the remineralization and prevention of demineralization of teeth
US7838046B2 (en) * 2001-09-26 2010-11-23 Tampa Bay Research Institute Plant extracts and uses thereof
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP4669960B2 (ja) 2003-06-03 2011-04-13 株式会社 メドレックス 局所麻酔薬を含有する口中用または咽頭部用製剤
US20070185194A1 (en) * 2003-07-01 2007-08-09 Kamal Mehta Stable oral compositions of azithromycin monohydrate
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US8518383B2 (en) 2006-02-03 2013-08-27 Wm. Wrigley Jr. Company Oral care products comprising buffer systems for improved mineralization/remineralization benefits
MX2008012524A (es) * 2006-04-05 2008-10-10 Cadbury Adams Usa Llc Complejo de fosfato de calcio y sales en sistemas de liberacion oral.
TWI445540B (zh) * 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
JP5166780B2 (ja) * 2007-06-20 2013-03-21 花王株式会社 液体口腔用組成物
US20090023771A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
US9358242B2 (en) * 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US20090130232A1 (en) 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
US20090239957A1 (en) * 2007-12-21 2009-09-24 Alcon Research, Ltd. Stabilized glycerophosphate-containing surgical irrigating solution
CN101980700A (zh) * 2008-02-20 2011-02-23 密苏里大学董事会 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
JP2009235012A (ja) 2008-03-28 2009-10-15 Gc Corp 口腔湿潤用組成物
EP2349189B1 (en) 2008-11-14 2015-08-05 Swissdent Cosmetics AG Biomimetic oral care composition
CN101584889B (zh) 2009-07-10 2012-12-12 山东大学威海分校 一种用于治疗牙周病的外用原位成型基质
US20110086108A1 (en) 2009-10-12 2011-04-14 Bartholomew Weldon Dissolving powders that can be mixed with water and used as an oral rinse
JP5485677B2 (ja) 2009-12-16 2014-05-07 花王株式会社 口腔用組成物
KR102120160B1 (ko) * 2010-08-07 2020-06-08 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 구강용 조성물
US11090259B2 (en) * 2012-11-16 2021-08-17 Eusa Pharma (Uk) Ltd Effervescent tablet

Also Published As

Publication number Publication date
EP3233092A4 (en) 2018-08-01
US20160175356A1 (en) 2016-06-23
AU2015367208A1 (en) 2017-08-03
KR102397070B1 (ko) 2022-05-16
CA2971224A1 (en) 2016-06-23
KR20170105517A (ko) 2017-09-19
BR112017013158B1 (pt) 2023-05-02
EP3233092A1 (en) 2017-10-25
US11590165B2 (en) 2023-02-28
US20230241102A1 (en) 2023-08-03
AU2015367208B2 (en) 2021-04-01
CN107530374B (zh) 2021-07-27
CA2971224C (en) 2020-09-22
MX2017007741A (es) 2018-05-02
WO2016095036A1 (en) 2016-06-23
BR112017013158A2 (pt) 2018-04-10
CN107530374A (zh) 2018-01-02
EP3233092B1 (en) 2019-09-04
MX372952B (es) 2020-04-03
JP2018505862A (ja) 2018-03-01

Similar Documents

Publication Publication Date Title
Ruengrungsom et al. Evaluation of F, Ca, and P release and microhardness of eleven ion-leaching restorative materials and the recharge efficacy using a new Ca/P containing fluoride varnish
US20230241102A1 (en) Formulations of calcium and phosphate for oral inflammation
CN104023796B (zh) 口腔护理组合物
CN102264636A (zh) 用于减少牙齿的脱矿质的组合物和方法
KR101642537B1 (ko) 푸시드산나트륨을 사용하고 생체중합체를 혼입한 약용 푸시드산 크림 및 이의 제조 방법
CA3082720A1 (en) Emulsions for treating mucosal infections
CN105078781B (zh) 龋齿的无创伤治疗用的木瓜蛋白酶牙科用凝胶组合物及其制备方法
CN101072550B (zh) 稳定的氧释放组合物
US9433644B2 (en) Formulations and methods for treating oral inflammation, injury, or pain
US20110086108A1 (en) Dissolving powders that can be mixed with water and used as an oral rinse
CN112121157A (zh) 基于增强型维生素d3的组合物、口腔护理凝胶及其应用
JPH03109315A (ja) 歯磨組成物
Acharya et al. Use of nanoparticles in pediatric dentistry: A narrative review
JP2006117539A (ja) 油性軟膏剤
CN104968317A (zh) 含无定形磷酸钙的局部用泛醇口腔补充组合物
CN101677940B (zh) 一种治疗鼻出血的组合物
RU2760268C1 (ru) Средство для гигиены полости рта
CN106580941B (zh) 一种含有薁磺酸钠的漱口散剂及其制备方法
JPH06305945A (ja) 歯磨用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201016

R150 Certificate of patent or registration of utility model

Ref document number: 6781701

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250